The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Previous

Second All-Oral Hep C Treatment Available: Less Expensive

Back to News Homepage

Next

Hold Onto Your Hats: Has a Vaccine for Hepatitis C Arrived?

A Win for Liver Transplant Patients with Hepatitis C

November 25, 2014

Print this page

AbbVie’s Hepatitis C drug recently cured 97% patients in a transplant study.

Europe gives green light to AbbVie hepatitis C drugs, others

(Reuters) – European regulators recommended approval for two drugs made by AbbVie to treat hepatitis C, both of which belong to a new generation of medicines that have proved effective in treating a condition that is the most common cause of liver transplants in Europe.

Dasabuvir, known commercially as Exviera, and a combination therapy called Viekirax, gave physicians additional treatment options with high cure rates, the European Medicines Agency said on Friday.

Continue reading this entire article:
http://www.reuters.com/article/2014/11/21/us-europe-medicine-approvals-idUSKCN0J518920141121

4 Comments
Share
Share

Previous

Second All-Oral Hep C Treatment Available: Less Expensive

Back to News Homepage

Next

Hold Onto Your Hats: Has a Vaccine for Hepatitis C Arrived?

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.